Xtant Medical Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 01, 2023 at 07:21 am EDT
Share
Xtant Medical Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 20.23 million compared to USD 15.28 million a year ago. Net loss was USD 2.19 million compared to USD 1.71 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
For the six months, revenue was USD 38.18 million compared to USD 28.24 million a year ago. Net loss was USD 4.27 million compared to USD 3.92 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.04 a year ago.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.